CC
CORT icon

Centiva Capital’s Corcept Therapeutics CORT Stock Holding History

Centiva Capital’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-5,419
Closed -$273K – 1626
2024
Q4 		$273K Buy
+5,419
New +$284K 0.01% 1196
2024
Q1 		– Sell
-13,498
Closed -$438K – 1849
2023
Q4 		$438K Buy
+13,498
New +$371K 0.01% 1021
2023
Q2 		– Sell
-24,297
Closed -$526K – 1676
2023
Q1 		$526K Buy
+24,297
New +$533K 0.01% 813

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Centiva Capital's CORT Position: Q1 2025 in Review

Centiva Capital sold out of Corcept Therapeutics (CORT) in Q1 2025, closing a stake of 5,419 shares — an estimated $273K sold.

Centiva Capital first reported a position in CORT in Q1 2023 and held it in 3 quarters. The position peaked at $526K in Q1 2023. 422 funds tracked by Wall St. Rank hold CORT as of Q1 2025.

  • Centiva Capital reported no remaining Corcept Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Centiva Capital sold 5,419 Corcept Therapeutics shares in Q1 2025, an estimated $273K.
  • Centiva Capital first reported a position in Corcept Therapeutics in Q1 2023 and held it in 3 quarters.
  • Centiva Capital's Corcept Therapeutics position peaked at $526K in Q1 2023.
  • 422 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q1 2025.

Based on Centiva Capital's 13F filing for Q1 2025, filed 15 May 2025.